Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.ABSTRACTMood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Natalie W Wu Benjamin S Maxey Amy L Ren Kenna N Leethy Brook Girma Amira Odisho Jessica S Kaye Aaron J Kaye Adam M Kaye Alan D Kaye George Mychaskiw Omar Viswanath Ivan Urits Source Type: research

Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in advers...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Brexanolone to Treat Postpartum Depression in Adult Women
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.ABSTRACTZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Furth...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Elyse M Cornett Lauren Rando Austin M Labb é Wil Perkins Adam M Kaye Alan David Kaye Omar Viswanath Ivan Urits Source Type: research

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Psychopharmacol Bull. 2021 Mar 16;51(2):131-148.ABSTRACTInfertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infert...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Nancy S Silverblatt Hayley E Vervaeke Cassidy C Horton Eden Girma Alan D Kaye Adam Kaye Jessica S Kaye Andrew J Garcia Elisa E Neuchat Treniece N Eubanks Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.ABSTRACTMood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Natalie W Wu Benjamin S Maxey Amy L Ren Kenna N Leethy Brook Girma Amira Odisho Jessica S Kaye Aaron J Kaye Adam M Kaye Alan D Kaye George Mychaskiw Omar Viswanath Ivan Urits Source Type: research

Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in advers...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Brexanolone to Treat Postpartum Depression in Adult Women
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.ABSTRACTZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Furth...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Elyse M Cornett Lauren Rando Austin M Labb é Wil Perkins Adam M Kaye Alan David Kaye Omar Viswanath Ivan Urits Source Type: research

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Psychopharmacol Bull. 2021 Mar 16;51(2):131-148.ABSTRACTInfertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infert...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Nancy S Silverblatt Hayley E Vervaeke Cassidy C Horton Eden Girma Alan D Kaye Adam Kaye Jessica S Kaye Andrew J Garcia Elisa E Neuchat Treniece N Eubanks Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.ABSTRACTMood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Natalie W Wu Benjamin S Maxey Amy L Ren Kenna N Leethy Brook Girma Amira Odisho Jessica S Kaye Aaron J Kaye Adam M Kaye Alan D Kaye George Mychaskiw Omar Viswanath Ivan Urits Source Type: research

Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in advers...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Brexanolone to Treat Postpartum Depression in Adult Women
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.ABSTRACTZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Furth...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Elyse M Cornett Lauren Rando Austin M Labb é Wil Perkins Adam M Kaye Alan David Kaye Omar Viswanath Ivan Urits Source Type: research

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Psychopharmacol Bull. 2021 Mar 16;51(2):131-148.ABSTRACTInfertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infert...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Nancy S Silverblatt Hayley E Vervaeke Cassidy C Horton Eden Girma Alan D Kaye Adam Kaye Jessica S Kaye Andrew J Garcia Elisa E Neuchat Treniece N Eubanks Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.ABSTRACTMood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Natalie W Wu Benjamin S Maxey Amy L Ren Kenna N Leethy Brook Girma Amira Odisho Jessica S Kaye Aaron J Kaye Adam M Kaye Alan D Kaye George Mychaskiw Omar Viswanath Ivan Urits Source Type: research

Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in advers...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Brexanolone to Treat Postpartum Depression in Adult Women
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.ABSTRACTZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Furth...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Elyse M Cornett Lauren Rando Austin M Labb é Wil Perkins Adam M Kaye Alan David Kaye Omar Viswanath Ivan Urits Source Type: research

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Psychopharmacol Bull. 2021 Mar 16;51(2):131-148.ABSTRACTInfertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infert...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Nancy S Silverblatt Hayley E Vervaeke Cassidy C Horton Eden Girma Alan D Kaye Adam Kaye Jessica S Kaye Andrew J Garcia Elisa E Neuchat Treniece N Eubanks Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.ABSTRACTMood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Natalie W Wu Benjamin S Maxey Amy L Ren Kenna N Leethy Brook Girma Amira Odisho Jessica S Kaye Aaron J Kaye Adam M Kaye Alan D Kaye George Mychaskiw Omar Viswanath Ivan Urits Source Type: research

Lamotrigine and Stevens-Johnson Syndrome Prevention
Psychopharmacol Bull. 2021 Mar 16;51(2):96-114.ABSTRACTStevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related-common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in advers...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Long H Nguyen Mary Jo Fitz-Gerald Erin Crane Kyle Lewis Samantha St Pierre Alan D Kaye Adam M Kaye Jessica S Kaye Rachel J Kaye Sonja A Gennuso Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Brexanolone to Treat Postpartum Depression in Adult Women
Psychopharmacol Bull. 2021 Mar 16;51(2):115-130.ABSTRACTZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Furth...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Elyse M Cornett Lauren Rando Austin M Labb é Wil Perkins Adam M Kaye Alan David Kaye Omar Viswanath Ivan Urits Source Type: research

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Psychopharmacol Bull. 2021 Mar 16;51(2):131-148.ABSTRACTInfertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infert...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Amber N Edinoff Nancy S Silverblatt Hayley E Vervaeke Cassidy C Horton Eden Girma Alan D Kaye Adam Kaye Jessica S Kaye Andrew J Garcia Elisa E Neuchat Treniece N Eubanks Giustino Varrassi Omar Viswanath Ivan Urits Source Type: research

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder
CONCLUSIONS: The KIOS focus on change illuminates problems in the same way that humans experience them, implying that the future state will be consequent to changes made to impact the current state. Randomized clinical trial is indicated.PMID:34092819 | PMC:PMC8146566 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Charles L Bowden Richard Priesmeyer Mauricio Tohen Vivek Singh Joseph R Calabrese Terry Ketter Andrew Nierenberg Michael E Thase Gregg Siegel Leslie H Siegel Jim Mintz Rif S El-Mallakh Susan L McElroy Melissa Martinez Source Type: research

Clozapine Prolongs Cortical Silent Period in Patients with Treatment-Resistant Schizophrenia
CONCLUSIONS: The present study indicated that CSP was prolonged in patients receiving clozapine, and suggested that clozapine enhances the transmission signal via GABAB receptors.PMID:34092820 | PMC:PMC8146563 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Atsuhiro Miyazawa Nobuhisa Kanahara Yusuke Nakata Satoshi Kodama Hiroshi Kimura Atsushi Kimura Yasunori Oda Hiroyuki Watanabe Masaomi Iyo Source Type: research

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
CONCLUSION: Thus, the effect of genetic polymorphism of the CYP3A4, CYP2C9, CYP2C9, CYP3A5, ABCB1, CYP2C19, CYP2C19, CYP2C19, SCL6A4, 5-HTR2A gene on the efficacy and safety profiles of mirtazapine was not demonstrated in a group of 108 patients with depressive disorder and alcohol use disorder.PMID:34092821 | PMC:PMC8146558 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: M S Zastrozhin VYu Skryabin VYu Smirnov A K Zastrozhina E V Kaverina D A Klepikov E A Grishina K A Ryzhikova I V Bure E A Bryun D A Sychev Source Type: research

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.ABSTRACTOBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial.METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) sc...
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Azmi Nasser Tesfaye Liranso Toyin Adewole Nicholas Fry Joseph T Hull Fatima Chowdhry Gregory D Busse Zare Melyan Andrew J Cutler Robert L Findling Stefan Schwabe Source Type: research

Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature
Psychopharmacol Bull. 2021 Mar 16;51(2):65-68.NO ABSTRACTPMID:34092823 | PMC:PMC8146564 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 7, 2021 Category: Psychiatry & Psychology Authors: Ayesha Kar Archana Adikey Jennifer Wells Anita Kablinger Source Type: research